Karyopharm Therapeutics (NASDAQ:KPTI) Given “Outperform” Rating at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a report released on Monday,Benzinga reports. Royal Bank of Canada currently has a $3.00 target price on the stock.

KPTI has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, January 15th. Piper Sandler raised their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Down 1.3 %

NASDAQ:KPTI opened at $0.62 on Monday. Karyopharm Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.70. The stock’s fifty day moving average is $0.69 and its two-hundred day moving average is $0.78. The stock has a market capitalization of $78.60 million, a price-to-earnings ratio of -0.55 and a beta of 0.06.

Institutional Trading of Karyopharm Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC increased its position in shares of Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after purchasing an additional 56,613 shares during the last quarter. FMR LLC increased its holdings in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after buying an additional 76,510 shares during the last quarter. AQR Capital Management LLC raised its stake in Karyopharm Therapeutics by 494.5% in the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after buying an additional 622,194 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Karyopharm Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after buying an additional 43,856 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its position in shares of Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after acquiring an additional 792,283 shares in the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).